M&A / Deals Aligos and Xiamen Amoytop sign deal for HBV therapy Pharmaceutical TechnologyAligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaceutical Technology Aligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection. M&A / DealsRead full story Post navigation Previous: The innovators working to make in vivo cell therapy a realityNext: Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026